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The changing epidemiology of pneumococcal diseases: New challenges after widespread routine 1 
immunization 2 
3 
Though the use of the pneumococcal conjugate vaccines (PCVs) has reduced the incidence of 4 
pneumonia and invasive diseases around the world, widespread vaccine use has resulted in serotype 5 
replacement (1). Serotype replacement describes the shifting burden of invasive pneumococcal 6 
disease, from vaccine serotypes to other serotypes not covered by the vaccine, which may, 7 
paradoxically, increase disease burden (2). This has created new challenges like detecting non-vaccine 8 
pneumococcus strains, identifying changes in disease transmission patterns, and raised questions 9 
about adapting immunization strategies. 10 
11 
Pneumococcal diseases are most commonly caused by 10 to 13 bacterial serotypes and current 12 
vaccines are designed to work against these. The remaining 80 serotypes are usually considered rare, 13 
but after widespread vaccine-use, they are seen more often. The best serotype test is time-consuming 14 
and expensive, requires highly trained technical stave, and is difficult to scale up to process large 15 
numbers of samples (3). This results in less testing, so the true burden of non-vaccine serotypes is 16 
unknown. Recently, the field of pneumococcal diagnostics has shifted towards molecular-based 17 
techniques utilizing the voluminous data from the Global Pneumococcus Sequencing Project 18 
(https://www.pneumogen.net/gps/). Multiplex-PCR tests are especially promising because they can 19 
identify non-vaccine serotypes, are easy to use, and samples can be processed in huge batches (4). 20 
21 
The transmission pattern of pneumonia is also changing. Pneumococcus colonizes the nasopharynx, 22 
while 30-80% of healthy children carry the bacteria, (5) and colonization rates are highest in developing 23 
countries (5). Since children are known reservoirs for disease-causing serotypes, controlling infection in 24 
this age group is crucial to public health. In countries with mature immunization programs, the vaccine 25 
serotypes are rarely seen in infants and younger children and pneumonia incidence has declined 22% 26 
across the population (6). Nonetheless,  in some countries, such as the UK, a recent epidemiologic 27 
assessment found increased incidence of invasive diseases not covered by the vaccine (7). The 28 
increase in disease burden among the elderly was 4% after 10 years of sustained high childhood 29 
immunization coverage (7). This is a group not targeted by routine PCV immunization, but was expected 30 
to benefit from high immunization coverage in children through herd immunity. 31 
32 
Our understanding that pneumococcal disease is controlled through the herd effect has been thrown 33 
into question. In most high-income countries, the herd effect becomes almost immediately apparent 34 
after the vaccine is introduced, but in developing countries the effect is more gradual (8). In high-income 35 
countries, serotype replacement seems to erode the effectiveness of a vaccine after long-term use, 36 
illustrated by the growing number of cases of invasive disease in adults. It is too early to tell if this is the 37 
case in developing countries since the vaccine was newly introduced and the program has not matured 38 
(8). We also do not know if transmission patterns will change since, as yet, there is little adult 39 
nasopharyngeal data from developing countries. We can expect more data in the future because many 40 
countries have set-up nationwide surveillance monitoring of the post-routine immunization period. 41 
 42 
We need more studies to determine the optimal vaccine schedule for pneumococcal vaccines, as the 43 
Strategic Advisory Group of Experts for Immunization pointed out in their latest meeting (October 2017) 44 
(9). All countries have chosen different vaccine products, targeted different age groups, and has 45 
established campaigns or phased-introduction and/or varying schedules. Given the wide variation in 46 
routine immunization programs in different countries, it is difficult to evaluate specific outcomes of 47 
interest like nasopharyngeal carriage, herd immunity, duration of protection, and transmission dynamics 48 
(8, 10). However, policymakers need to know the optimal dosing schedule so they can set the number 49 
of doses and shot schedules, as these factors guide implementation and determine costs for 50 
immunization programs. 51 
 52 
The epidemiology of pneumococcal diseases will change as the pathogen evolves in response to 53 
vaccine-induced population immunity. Non-vaccine serotypes will likely dominate transmission cycles 54 
among carriers. When non-vaccine pneumococci become more invasive, we will see a higher proportion 55 
of them in those who present with the disease. Newer serotypes will also evolve in response to vaccine-56 
induced herd immunity, raising new challenges for serotyping testing, for predicting disease 57 
transmission patterns and optimizing immunization schedules. All these challenges must be met if we 58 




1. Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae 63 
causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS 64 
One. 2017;12(5):e0177113. 65 
2. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal 66 
vaccination. Lancet. 2011;378(9807):1962-73. 67 
3. Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal 68 
Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev. 2015;28(3):871-99. 69 
4. Jauneikaite E, Tocheva AS, Jefferies JM, Gladstone RA, Faust SN, Christodoulides M, et al. 70 
Current methods for capsular typing of Streptococcus pneumoniae. J Microbiol Methods. 2015;113:41-71 
9. 72 
5. Usuf E, Bottomley C, Adegbola RA, Hall A. Pneumococcal carriage in sub-Saharan Africa--a 73 
systematic review. PLoS One. 2014;9(1):e85001. 74 
6. McAllister DA, Liu L, Shi T, Chu Y, Reed C, Burrows J, et al. Global, regional, and national 75 
estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 76 
2015: a systematic analysis. The Lancet Global Health. 2019;7(1):e47-e57. 77 
7. Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, et al. Rapid increase in 78 
non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a 79 
prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441-51. 80 
8. International Vaccine Access Center. Pneumococcal Conjugate Vaccine Review of Impact 81 
Evidence: summary of findings from systematic review. Baltimore, MD: Johns Hopkins Bloomberg 82 
School of Public Health; 2017. 83 
9. World Health Organization. Meeting of the Strategic Advisory Group of Experts on 84 
immunization, October 2017 – conclusions and recommendations. Wkly Epidmiol Rec. 85 
2017;92(48):729. 86 
10. Shiri T, Datta S, Madan J, Tsertsvadze A, Royle P, Keeling MJ, et al. Indirect effects of 87 
childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review 88 
and meta-analysis. Lancet Global Health. 2017;5(1):e51-e9. 89 
 90 
